RT Journal Article
SR Electronic
T1 Covid-19 Vaccine Effectiveness in Healthcare Personnel in six Israeli Hospitals (CoVEHPI)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.30.21262465
DO 10.1101/2021.08.30.21262465
A1 Katz, Mark A.
A1 Harlev, Efrat Bron
A1 Chazan, Bibiana
A1 Chowers, Michal
A1 Greenberg, David
A1 Peretz, Alon
A1 Tshori, Sagi
A1 Levy, Joseph
A1 Yacobi, Mili
A1 Hirsch, Avital
A1 Amichay, Doron
A1 Weinberger, Ronit
A1 Dor, Anat Ben
A1 Taraday, Elena Keren
A1 Reznik, Dana
A1 Chayat, Chen Barazani
A1 Sagas, Dana
A1 Zvi, Haim Ben
A1 Berdinstein, Rita
A1 Rashid, Gloria
A1 Avni, Yonat Shemer
A1 Mandelboim, Michal
A1 Zuckerman, Neta
A1 Rainy, Nir
A1 Akriv, Amichay
A1 Dagan, Noa
A1 Kepten, Eldad
A1 Barda, Noam
A1 Balicer, Ran D.
YR 2021
UL http://medrxiv.org/content/early/2021/09/02/2021.08.30.21262465.abstract
AB Background Methodologically rigorous studies on Covid-19 vaccine effectiveness (VE) in preventing SARS-CoV-2 infection are critically needed to inform national and global policy on Covid-19 vaccine use. In Israel, healthcare personnel (HCP) were initially prioritized for Covid-19 vaccination, creating an ideal setting to evaluate real-world VE in a closely monitored population.Methods We conducted a prospective study among HCP in 6 hospitals to estimate the effectiveness of the BNT162b2 mRNA Covid-19 vaccine in preventing SARS-CoV-2 infection. Participants filled out weekly symptom questionnaires, provided weekly nasal specimens, and three serology samples – at enrollment, 30 days and 90 days. We estimated VE against PCR-confirmed SARS-CoV-2 infection using the Cox Proportional Hazards model and against a combined PCR/serology endpoint using Fisher’s exact test.Findings Of the 1,567 HCP enrolled between December 27, 2020 and February 15, 2021, 1,250 previously uninfected participants were included in the primary analysis; 998 (79.8%) were vaccinated with their first dose prior to or at enrollment, all with Pfizer BNT162b2 mRNA vaccine. There were four PCR-positive events among vaccinated participants, and nine among unvaccinated participants. Adjusted two-dose VE against any PCR- confirmed infection was 94.5% (95% CI: 82.6%-98.2%); adjusted two-dose VE against a combined endpoint of PCR and seroconversion for a 60-day follow-up period was 94.5% (95% CI: 63.0%-99.0%). Five PCR-positive samples from study participants were sequenced; all were alpha variant.Interpretation Our prospective VE study of HCP in Israel with rigorous weekly surveillance found very high VE for two doses of Pfizer BNT162b2 mRNA vaccine against SARS-CoV-2 during a period of predominant alpha variant circulation.Funding Clalit Health ServicesCompeting Interest StatementMAK, JL, MY, AH, AA, EK, ND, NB, and RDB report institutional grants to Clalit Research Institute from Pfizer outside the submitted work and unrelated to COVID-19, with no direct or indirect personal benefits. No other authors report any conflicts of interest. Clinical TrialClinicalTrials.gov Identifier: NCT04709003Funding StatementClalit Health Services funded this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the Clalit Health Services Central Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesBecause of data privacy regulations, the raw data for this study cannot be publicly shared.